ALPCO Diagnostics Exclusively Offers Animal NGAL Assays from BioPorto
Salem, NH, June 17, 2010 --(PR.com)-- BioPorto Diagnostics has awarded ALPCO Diagnostics
exclusive distributorship for its animal NGAL ELISAs to the North American market. BioPorto's
prominence is unrivaled in immunoassays for measuring NGAL (neutrophil gelatinase associated
lipocalin) - the breakthrough kidney injury marker that was brought to market first by BioPorto. In
Europe, NGAL is used to diagnose Acute Kidney Injury (AKI) within a few hours after an AKI causing
event has occurred - a vast improvement over all other methods used to date. The availability of these
assays can translate into considerable improvements in toxicity testing for the medical and drug industry
in North America.
Sean Conley, President of ALPCO Diagnostics is excited about BioPorto's NGAL Assays: “We are very
pleased to offer the BioPorto NGAL products to the North American life science research markets.
BioPorto has a proven reputation for producing high quality immunoassay products and offers the most
comprehensive NGAL product range including Canine NGAL ELISA, Mouse NGAL ELISA, and Rat
NGAL ELISA with Porcine NGAL ELISA and Monkey NGAL ELISA launching soon.”
“ALPCO is a well established and reputable company in the life sciences industry and we are very
pleased to have the opportunity to work together. A primary focus will be the promotion of our animal
NGAL product line aimed at the pharmaceutical industry - ALPCO's renowned competencies in this area
coupled with the unmatched depth of our NGAL portfolio is a winning combination” says Thea Olesen,
CEO, BioPorto Diagnostics.
For more information, visit www.NGAL.com. Alternatively BioPorto will be presenting scientific posters
at the upcoming World Pharmaceutical Congress on some of latest breakthroughs with these assays while
ALPCO will be available at booth #18 in the exhibitor area.
About ALPCO Diagnostics
Founded in 1990, ALPCO Diagnostics is an importer and distributor of high quality research